[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552584":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":32,"locations":37,"responsibleParty":52,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"European Institute of Oncology","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Tamoxifen",null,"Patients who are receiving treatment with tamoxifen in adjuvant setting",[13],"Other: Skin tests",{"label":15,"type":10,"description":16,"interventionNames":17},"Aromatase Inhibitors","Patients who are receiving treatment with an aromatase inhibitor in adjuvant setting",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Paclitaxel","Patients who are receiving treatment with Paclitaxel in adjuvant setting",[13],[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"Skin tests","Acquisition of Skindex questionnaire 29 and execution of instrumental skin tests",[15,19,9],[28],{"name":29,"affiliation":30,"role":31},"Giulio Tosti, MD","European Istitute of Oncology","PRINCIPAL_INVESTIGATOR",[33],{"name":29,"role":34,"phone":35,"phoneExt":10,"email":36},"CONTACT","+39 0257489318","giulio.tosti@ieo.it",[38],{"facility":5,"status":39,"city":40,"state":10,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Milan","20141","Italy","IT",{"type":45,"coordinates":46},"Point",[47,48],9.18951,45.46427,{"lat":48,"lon":47},[51],{"name":29,"role":34,"phone":35,"phoneExt":10,"email":36},{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100552584","characterization-of-biophysical-and-mechanical-parameters-on-skin-of-breast-cancer-patients-100552584",false,"NCT06474988","Characterization of Biophysical and Mechanical Parameters on Skin of Breast Cancer Patients","Characterization of Biophysical and Mechanical Parameters on the Skin of Subjects With a Diagnosis of Breast Cancer After Surgery and Undergoing Adjuvant Treatment.","Inclusion Criteria:\n\n* age between 40 and 70 years\n* subjects who are receiving treatment with tamoxifen, aromatase inhibitor or paclitaxel in adjuvant therapy +\u002F- adjuvant radiotherapy\n* subjects who are receiving hormonal therapy must have suspended any chemotherapy for at least 30 days\n\nExclusion Criteria:\n\n* presence of known chronic skin pathologies before adjuvant treatment start (psoriasis, lupus, atopic dermatitis)\n* inability to understand and will\n* unavailability to carry out all the tests required by the protocol","ALL","40 Years","70 Years",{"count":65,"type":66},150,"ESTIMATED","OBSERVATIONAL","Aim of this study is to characterize the chemical\u002Fphysical and structural parameters of the skin in patients with breast cancer undergoing oncological adjuvant treatment in order to understand how to prevent and manage adverse skin events during hormone therapy, also through the formulation of new functional dermocosmetics.",[70,71],"Breast Cancer","Estrogen Receptor Positive Tumor",[73,74,75],"Estrogen Receptor Positive Breast Cancer","Adjuvant Treatment","Skin Toxicity","2024-06-20",{"date":78,"type":79},"2024-06-26","ACTUAL",{"date":81,"type":79},"2024-05-27",{"date":83,"type":66},"2025-05-31",{"name":5,"class":6},1]